Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
Completed
Novartis Pharmaceuticals
Phase 3
2005-02-01
This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir
in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir
(12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive
multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess
safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
Completed
Novartis Pharmaceuticals
Phase 3
2006-03-01
This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day
(b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms
compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
Famciclovir 500 mg Tablets Under Fasting Conditions
Completed
Teva Pharmaceuticals USA
Phase 1
2004-08-01
The objective of this study is to compare the relative bioavailability of famciclovir 500 mg
tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult
subjects under fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
